Viatical Settlement Broker vs. Direct Buyer — Why the Difference Costs Cancer Patients Tens of Thousands of Dollars
When a cancer patient begins exploring a viatical settlement they will encounter two fundamentally different types of companies — direct buyers and brokers. Most patients never know the difference exists. And that lack of knowledge costs them. A direct buyer makes one offer — calculated to benefit their own investors. A broker like Cancer Care Financial represents the patient exclusively — running a competitive auction among multiple buyers simultaneously to drive the offer to its true market maximum. The financial difference between these two approaches can be tens of thousands of dollars on the same policy. Cancer Care Financial is the nation’s leading viatical settlement broker specializing exclusively in cancer patients and seriously ill individuals — with a maximum 10% commission that is approximately two thirds lower than the 30% industry standard. Understanding this distinction before contacting any company is one of the most important steps a cancer patient can take to protect their financial interests.
What a Direct Viatical Settlement Buyer Actually Does
Direct buyers are institutional companies that purchase life insurance policies for their own investment portfolios or on behalf of investor funds. They are licensed, regulated, and operate legally within the viatical settlement industry.
But there is one fundamental reality every cancer patient must understand before contacting a direct buyer:
When you contact a direct buyer you receive one offer. That offer is calculated to benefit their investors — not you.
There is no auction. There is no competing bid driving the price higher. There is simply one number from one company — presented as if it represents the fair market value of your policy.
It almost never does.
A direct buyer’s business model depends on acquiring policies for as little as possible. The less they pay the more profitable the investment for their portfolio. Every dollar they do not pay a cancer patient is a dollar that stays in their investment fund.
That is not a criticism — it is simply how their business works. Understanding it is what protects cancer patients from accepting far less than their policy is actually worth.
What Cancer Care Financial Does Differently — The Broker Advantage
Cancer Care Financial is a licensed independent viatical settlement broker. The distinction is fundamental — and it changes everything about the financial outcome for the patient.
As a broker Cancer Care Financial has one obligation — to the patient. Not to any buyer. Not to any investor fund. To the person on the other end of the phone who needs the highest possible offer for their policy.
Here is how the broker model produces better outcomes:
The competitive auction: Every policy Cancer Care Financial brings to market enters a closed network of qualified institutional buyers simultaneously. Those buyers — including some of the largest direct buyers in the industry — must compete against each other in structured bidding rounds to win the policy. That competition drives offers upward round after round. A recent Cancer Care Financial transaction produced 22 bids between two competing buyers over a two week period — simply because both wanted the same policy and neither was willing to stop competing. That unpredictable upside belongs entirely to the patient.
Complete representation: Cancer Care Financial negotiates on behalf of the patient at every stage — pressing buyers to their absolute maximum and never accepting a current offer as final until the market has been fully exhausted.
Total transparency: Every offer is shared with the patient — gross amount first, complete transparency always. The patient sees every bid from every buyer before making any decision.
The lowest commission in the industry: Cancer Care Financial caps its commission at a strict maximum of 10% — averaging approximately 8% across transactions. The industry standard runs as high as 30%. That difference does not just affect the commission line — it fundamentally changes how much of the settlement reaches the patient.
The Real Dollar Difference — Why Commission Matters More Than Most Patients Realize
The commission difference between Cancer Care Financial and industry standard brokers is not a minor administrative detail. It is a significant financial outcome difference that scales with every policy.
Consider a cancer patient with a $300,000 life insurance policy. A competitive auction produces a gross offer of $200,000.
At a 30% industry standard commission — the patient receives $140,000.
At Cancer Care Financial’s maximum 10% commission — the patient receives $180,000.
That is $40,000 more reaching the patient from the exact same gross offer — money that funds treatment, covers living expenses, supports family, or pays for integrative care that insurance will not cover.
And that calculation assumes the gross offer is identical. In reality the competitive auction that Cancer Care Financial runs typically produces a higher gross offer than any single direct buyer would have made — meaning the actual difference in what reaches the patient is even greater.
The Three Types of Companies in the Viatical Settlement Space
Cancer patients researching viatical settlements encounter three distinct types of companies — and understanding the difference between them is essential before submitting any personal information to anyone.
Type 1 — Direct Buyers: Institutional companies that purchase policies for their own investment portfolios. They make single offers. Their obligation is to their investors. They are transparent about what they are. The problem is not deception — it is that a single offer with no competition never reflects true market value.
Type 2 — True Viatical Settlement Brokers: Licensed independent companies whose sole obligation is to the patient. They bring the complete policy file to multiple buyers simultaneously, create a competitive auction, and fight for the highest possible offer on behalf of the patient. Cancer Care Financial is a true broker.
Type 3 — Lead Generation Companies: Companies that present themselves as brokers, resources, or viatical settlement services — but actually collect patient information and sell it as a lead to buyers. There is no competitive auction. There is no representation. There is no advocate. The patient’s personal medical and financial information is the product being sold.
For a cancer patient sharing sensitive medical information this is particularly concerning. A lead generator collects diagnosis details, staging information, and policy details — and forwards them to buyers without ever running an auction or representing the patient’s interests in any way.
If You Already Have an Offer From a Direct Buyer
If you have already contacted a direct viatical settlement buyer and received an offer — it is not too late.
Cancer Care Financial offers a completely free no-obligation review of any existing offer from any direct buyer. We will evaluate whether that offer reflects true competitive market value — or whether our auction network would produce a materially higher result for your treatment and your family.
A single offer on the table is never the final word on what your policy is worth until it has been tested against real market competition. There is no cost and no obligation to find out — and the difference could be significant.
Frequently Asked Questions
A direct buyer purchases life insurance policies for their own investment portfolio — making a single offer calculated to benefit their investors. A viatical settlement broker like Cancer Care Financial represents the patient exclusively — bringing the policy to multiple buyers simultaneously and creating competitive bidding that drives the offer to its true market maximum. The broker's legal and ethical obligation is entirely to the patient. Cancer Care Financial caps its commission at a maximum of 10% — approximately two thirds lower than the 30% industry standard — ensuring the majority of every offer stays with the patient.
When you contact a direct buyer you receive one offer — calculated for their investors, not for you. Cancer Care Financial brings your policy to multiple qualified institutional buyers simultaneously and creates competitive bidding that drives your offer to its true market maximum. The commission Cancer Care Financial charges — capped at a maximum of 10% versus the 30% industry standard — is almost always more than offset by the higher offers competitive bidding produces. Additionally Cancer Care Financial offers a free review of any existing offer from a direct buyer — ensuring you never accept a single offer without knowing what the full market would have paid.
Yes. Many of the largest and most established direct buyers in the viatical settlement industry participate as buyers inside Cancer Care Financial's closed competitive auction network. When Cancer Care Financial brings your policy to market these companies compete against each other to win it — rather than presenting a single take-it-or-leave-it offer directly to you. Working with Cancer Care Financial means direct buyers must outbid each other to secure your policy — driving your final offer significantly higher than any single direct approach would produce.
Lead generation companies present themselves as viatical settlement brokers or resources but actually collect patient information — including sensitive medical and financial details — and sell it as a lead to buyers. There is no competitive auction. There is no patient representation. The patient's information is the product. For a cancer patient sharing diagnosis details and policy information this is a particularly important distinction. Cancer Care Financial is a licensed independent broker — not a lead generator. We represent you exclusively and run a genuine competitive auction on your behalf.
It is never too late before you have signed a closing agreement. Cancer Care Financial offers a completely free no-obligation review of any existing offer from any direct buyer. We will evaluate whether that offer reflects true competitive market value or whether our auction network would produce a materially higher result. There is no cost and no obligation to obtain that review — and it could represent a significant difference in what reaches you for your treatment and your family.
There are zero upfront costs at any stage. Cancer Care Financial absorbs all expenses related to policy analysis, medical underwriting, and running the competitive market auction. The commission is capped at a strict maximum of 10% — averaging approximately 8% — and is only deducted if a transaction successfully closes. No patient is ever obligated to accept any offer the auction produces. Cancer Care Financial will always give a completely honest assessment — including the recommendation to explore other options if a viatical settlement is not the right fit for your specific situation.